Retatrutide Explained: What a Triple Agonist Actually Does

When tirzepatide arrived as a dual GIP/GLP-1 agonist and produced better weight-loss results than semaglutide, the obvious question followed: what happens if you add a third receptor? That question is what retatrutide (LY3437943, developed by Eli Lilly) is designed to answer.

Retatrutide is a triple agonist — a single molecule that activates the GLP-1, GIP, and glucagon receptors simultaneously. The first two receptors are the same ones tirzepatide targets. The glucagon receptor is the new piece, and it changes the mechanism in ways that are pharmacologically interesting and clinically meaningful.

What GLP-1 and GIP Receptors Already Do

To understand why adding glucagon matters, it helps to be clear on what the first two receptors contribute.

GLP-1 receptor agonism (the mechanism behind semaglutide) produces:

• Reduced appetite and food intake via brain signaling
• Slowed gastric emptying (you feel full longer)
• Glucose-dependent insulin secretion from the pancreas
• Suppressed glucagon release after meals

GIP receptor agonism (the second arm of tirzepatide) adds:

• Additional appetite suppression via a different neural pathway
• Fat storage regulation — GIP affects how fat cells respond to insulin
• Possibly enhanced insulin secretion in a complementary pattern to GLP-1
• Less nausea at equivalent appetite-suppressing doses (one hypothesized reason tirzepatide has a somewhat better tolerability profile than semaglutide at matched doses)

Together, GLP-1 + GIP produce better outcomes than either alone — which the SURPASS trial program confirmed in head-to-head data against semaglutide.

What the Glucagon Receptor Adds

Glucagon is typically framed as insulin's opposing hormone — it raises blood sugar by signaling the liver to release glucose from glycogen stores. This is why GLP-1 drugs that suppress glucagon are useful in diabetes: less glucagon means better post-meal blood sugar control.

But glucagon has another, less-discussed function: it increases energy expenditure. Glucagon activation in brown adipose tissue (and potentially through central nervous system pathways) promotes thermogenesis — the burning of calories as heat. It also directly stimulates fat breakdown (lipolysis) in white adipose tissue.

The tradeoff is that activating glucagon raises blood sugar — the opposite of what you want in a diabetes drug. This is where the triple-agonist design becomes elegant: the GLP-1 and GIP components suppress blood glucose, creating enough of a glucose-lowering buffer to allow glucagon receptor activation without hyperglycemia. You get the energy-expenditure benefits of glucagon without the blood sugar spike.

This is meaningfully different from just adding more GLP-1 or more GIP. Glucagon agonism raises your metabolic rate independent of food intake — which is a category of effect that single- and dual-agonists don't produce.

Phase 2 Trial Results

Retatrutide's Phase 2 trial, published in the New England Journal of Medicine in 2023 (Jastreboff et al.), enrolled adults with obesity (no diabetes) and tested five dose regimens over 24 and 48 weeks.

At 48 weeks, participants on the highest dose studied (12 mg) lost approximately 24% of body weight — a result that, if replicated in Phase 3, would exceed tirzepatide's highest-dose results in SURMOUNT-1 (~21% at 72 weeks) and considerably exceed semaglutide's STEP-1 results (~15% at 68 weeks).

A few important caveats:

• Phase 2 trials are smaller than Phase 3 and typically involve closer monitoring and higher adherence
• The 48-week result wasn't the primary endpoint; the primary endpoint was 24 weeks
• The trial was not powered or designed for direct comparison to other drugs
• Side effects at higher doses were substantial: nausea and vomiting rates were meaningful, particularly early in titration

The evidence here is preliminary. The headline number is genuinely striking, but Phase 3 outcomes with a larger and more diverse population will determine whether it holds.

Where Retatrutide Stands Now

As of mid-2026, retatrutide is in Phase 3 clinical trials. Eli Lilly's Phase 3 program (TRIUMPH) is evaluating it for:

• Obesity without diabetes
• Type 2 diabetes
• Potentially cardiovascular outcomes (similar to the SELECT trial for semaglutide)

Regulatory approval is not expected before 2027 at the earliest in the US, pending Phase 3 readouts and FDA review.

Retatrutide is not available commercially in any market as of this writing. It is not available through compounding pharmacies (compounders cannot legally produce a non-shortage drug they don't have authorization to copy, and an unapproved IND drug is not eligible for 503A/503B compounding). Be skeptical of any vendor claiming to sell retatrutide.

How It Compares to the Current Options

The pattern is consistent — each added receptor appears to improve outcomes. Whether the pattern continues to hold in rigorous Phase 3 data is the central unanswered question.

What the Evidence Doesn't Tell Us Yet

A few things remain genuinely uncertain:

• Long-term safety of glucagon receptor agonism: raising energy expenditure through glucagon also has effects on the liver, heart rate, and bone metabolism that require longer-term study
• Tolerability at therapeutic doses: Phase 3 may reveal that higher glucagon activity produces side effects that didn't surface at Phase 2 scale
• Regain after discontinuation: no data exists yet on what happens when retatrutide users stop the drug
• Head-to-head data vs tirzepatide: the Phase 2 comparison is indirect and across different trial designs

The triple-agonist approach is scientifically coherent and the early data is compelling. But "compelling early data" describes a lot of drugs that didn't make it through Phase 3.

Related reading

• Tirzepatide: the complete guide
• Semaglutide: the complete guide
• GLP-1 weight loss: realistic timelines